Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme.

Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Abstract Text:

Allen M Chen,Susan Chang,Jean Pouliot,Penny K Sneed,Michael D Prados,Kathleen R Lamborn,Mary K Malec,Michael W McDermott,Mitchell S Berger,David A Larson,

PURPOSE: To evaluate the feasibility of gross total resection and permanent I-125 brachytherapy followed by hyperfractionated radiotherapy for patients with newly diagnosed glioblastoma. METHODS AND MATERIALS: From April 1999 to May 2002, 21 patients with glioblastoma multiforme were enrolled on a Phase I protocol investigating planned gross total resection and immediate placement of permanent I-125 seeds, followed by postoperative hyperfractionated radiotherapy to a dose of 60 Gy at 100 cGy b.i.d., 5 days per week. Median age and Karnofsky performance status were 50 years (range, 32-65 years) and 90 (range, 70-100), respectively. Toxicity was assessed according to Radiation Therapy Oncology Group criteria. RESULTS: Eighteen patients completed treatment according to protocol. The median preoperative tumor volume on magnetic resonance imaging was 18.6 cm(3) (range, 4.4-41.2 cm(3)). The median brachytherapy dose measured 5 mm radially outward from the resection cavity was 400 Gy (range, 200-600 Gy). Ten patients underwent 12 reoperations, with 11 of 12 reoperations demonstrating necrosis without evidence of tumor. Because of high toxicity, the study was terminated early. Median progression-free survival and overall survival were 57 and 114 weeks, respectively, but not significantly improved compared with historical patients treated at University of California, San Francisco, with gross total resection and radiotherapy without brachytherapy. CONCLUSIONS: Treatment with gross total resection and permanent I-125 brachytherapy followed by hyperfractionated radiotherapy as performed in this study results in high toxicity and reoperation rates, without demonstrated improvement in survival.

Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Publishing Authors By Initials

AM Chen,S Chang,J Pouliot,PK Sneed,MD Prados,KR Lamborn,MK Malec,MW McDermott,MS Berger,DA Larson,

For similar tumor burden research abstracts see: tumor burden research

PUBMED ID PMID:

MEDLINE DATE:

Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International journal of radiation oncology, biolo

VOLUME: 69

Page Numbers: 825-30

Journal Abbreviation: Int. J. Radiat. Oncol. Biol. P

ISSN: 0360-3016

DAY: 23

MONTH: 05

YEAR: 2007

Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603616

Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Keywords Mesh Terms:

KEYWORDS: Tumor Burden

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Information

Substance Name: Iodine Radioisotopes

Registry Number: 0

Grant and Affiliation Information for Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme.

AFFILIATION: Department of Radiation Oncology, University of California, San Francisco School of Medicine, San Francisco, CA 94143-0226, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Radiat Oncol Biol Phys

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme Related Publications

• Achieving Millennium Development Goals for health: building understanding, trust and capacity to respond.
• Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study.
• Alzheimer's disease medication: use and cost projections for Medicare Part D.
• Antimicrobial resistance patterns of colonizing flora on nurses' hands in the neonatal intensive care unit.
• Association of the built environment with physical activity and obesity in older persons.
• Characteristics of nurse practitioner curricula in the United States related to antimicrobial prescribing and resistance.
• Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses.
• Community factors in the development of antibiotic resistance.
• Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.
• Effect of angiotensin II on primary cardiac fibroblast matrix metalloproteinase activities.
• Effects of analytic variations in creatinine measurements on the classification of renal disease using estimated glomerular filtration rate (eGFR).
• Emergence of resistant staphylococci on the hands of new graduate nurses.
• Endocrine responses and estrous activity in Holstein heifers fed supplemental beta-carotene.
• Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
• Improving participant comprehension in the informed consent process.
• In vivo confocal microscopy of polymorphic amyloid degeneration and posterior crocodile shagreen.
• Knowledge, attitudes, and practices regarding antibiotic use among Latinos in the United States: review and recommendations.
• Mast cells accumulate in the anogenital region of somatosensory thalamic nuclei during estrus in female mice.
• Mechanism of polymer drag reduction using a low-dimensional model.
• Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme.
• Protective association between neighborhood walkability and depression in older men.
• Risk factors for late-onset health care-associated bloodstream infections in patients in neonatal intensive care units.
• Staphylococcus aureus colonization and infection in New York State prisons.
• Structure, topology, and tilt of cell-signaling peptides containing nuclear localization sequences in membrane bilayers determined by solid-state NMR and molecular dynamics simulation studies.
• The animal welfare information center: helping the community meet the information requirement of the three rs.
• The relationship between moral distress and perception of futile care in the critical care unit.
• Transposon Tn10-dependent expression of the lamB gene in Escherichia coli.
• Voice F0 responses to pitch-shifted voice feedback during English speech.
• Warned, but not well armed: preventing viral upper respiratory infections in households.
• [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity.